CASP3 and melanoma: In vitro studies on human melanoma G-361 cells demonstrated that the co-treatment increased ROS production and upregulated the expression levels of pro-apoptotic proteins (i.e., caspases 3, 7, 8 and 9) while decreasing DNA damage.